Price
Financials
Consolidated, Rs crore| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 197 | 219 | 228 | 246 | 260 | 266 | 282 |
| Expenses | 153 | 168 | 180 | 182 | 199 | 215 | 221 |
| Operating Profit | 44 | 51 | 48 | 64 | 61 | 51 | 60 |
| OPM % | 22% | 23% | 21% | 26% | 23% | 19% | 21% |
| Other Income | 5 | 4 | 7 | 4 | 3 | 12 | 7 |
| Interest | 5 | 6 | 6 | 45 | 6 | 3 | 2 |
| Depreciation | 18 | 19 | 20 | 23 | 22 | 26 | 25 |
| Profit before tax | 26 | 30 | 29 | -1 | 36 | 33 | 41 |
| Tax % | 24% | 17% | 17% | 1,427% | 11% | 9% | 22% |
| Net Profit | 20 | 25 | 24 | -9 | 32 | 30 | 32 |
| EPS in Rs | 96.50 | 119.30 | 13.10 | -5.24 | 3.21 | 3.03 | 3.19 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales | 286 | 318 | 437 | 566 | 756 | 999 | 1,053 |
| Expenses | 248 | 302 | 389 | 465 | 589 | 774 | 817 |
| Operating Profit | 37 | 16 | 49 | 101 | 167 | 225 | 236 |
| OPM % | 13% | 5% | 11% | 18% | 22% | 23% | 22% |
| Other Income | 5 | 10 | 6 | 8 | 14 | 23 | 26 |
| Interest | 7 | 10 | 16 | 20 | 21 | 60 | 56 |
| Depreciation | 34 | 42 | 47 | 56 | 72 | 91 | 96 |
| Profit before tax | 1 | -27 | -9 | 33 | 87 | 97 | 110 |
| Tax % | 31% | -21% | 37% | -6% | 23% | 21% | |
| Net Profit | 1 | -21 | -12 | 35 | 67 | 77 | 85 |
| EPS in Rs | 3.40 | -106.93 | -58.69 | 169.82 | 321.87 | 7.66 | 4.19 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 28% | 32% | 32% | ||
| Compounded Profit Growth | % | 162% | 103% | 12% | ||
| Stock Price CAGR | % | % | % | % | ||
| Return on Equity | % | 6% | 10% | 9% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 20 |
| Reserves | 245 | 391 | 384 | 409 | 579 | 1,096 |
| Borrowings | 140 | 119 | 200 | 271 | 261 | 80 |
| Other Liabilities | 42 | 59 | 81 | 124 | 153 | 271 |
| Total Liabilities | 428 | 571 | 666 | 806 | 994 | 1,467 |
| Fixed Assets | 192 | 205 | 239 | 356 | 396 | 517 |
| CWIP | 2 | 43 | 34 | 1 | 6 | 6 |
| Investments | 0 | 0 | 0 | 0 | 51 | 178 |
| Other Assets | 234 | 322 | 393 | 449 | 542 | 767 |
| Total Assets | 428 | 571 | 666 | 806 | 994 | 1,467 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity | 32 | 14 | 11 | 72 | 135 | 233 |
| Cash from Investing Activity | -62 | -130 | -76 | -52 | -125 | -392 |
| Cash from Financing Activity | 36 | 121 | 60 | 27 | 54 | 157 |
| Net Cash Flow | 5 | 6 | -4 | 47 | 65 | -2 |
| Free Cash Flow | -29 | -64 | -62 | -8 | 35 | 113 |
| CFO/OP | 49% | 119% | 14% | 80% | 82% | 116% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 101 | 123 | 132 | 131 | 129 | 116 |
| Inventory Days | 65 | 50 | 67 | |||
| Days Payable | 56 | 70 | 63 | |||
| Cash Conversion Cycle | 110 | 103 | 137 | 131 | 129 | 116 |
| Working Capital Days | 26 | 55 | 19 | 56 | 27 | 42 |
| ROCE % | -4% | 1% | 8% | 14% | 15% |
| Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Promoters | 63.85% | 63.85% | 63.85% |
| FIIs | 9.30% | 9.94% | 8.78% |
| DIIs | 8.10% | 8.64% | 9.05% |
| Public | 18.74% | 17.56% | 18.30% |
| No. of Shareholders | 67,416 | 43,409 | 44,091 |
Fundamentals
Market Cap₹ 6,671 Cr.
Current Price₹ 663
Stock P/E78.4
Book Value₹ 111
ROCE15.3 %
ROE8.83 %
Dividend Yield0.00 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)32%
Compounded Profit Growth (TTM)12%
Consolidated figures.
Valuation
Market capRs 6,526 Cr
Enterprise valueRs 6,501 Cr
P/E (TTM)110.21x
Price to book16.62x
Price to sales7.33x
EV / EBITDA28.66x
EV / EBIT44.43x
EV / sales7.31x
Price to cash flow454.76x
Earnings yield0.91%
Profitability
Operating margin (excl. other income)5.08%
Operating margin (incl. other income)8.08%
EBITDA margin25.49%
Pre-tax margin9.47%
Net profit margin6.65%
Net margin, latest quarter-3.85%
ROE-6.67%
ROCE-3.75%
ROA-4.27%
ROIC (approx.)31.24%
Tax rate21.44%
Other income / net worth2.43%
Growth
Sales growth (latest year)11.17%
Profit growth (latest year)-3596.72%
Sales growth QoQ7.88%
Profit growth QoQ-139.96%
Per share
EPS (TTM)Rs 5.89
EPS (latest year)Rs -106.93
EPS (latest quarter)Rs -0.94
Book value per shareRs 39.04
Sales per shareRs 88.50
Cash flow per shareRs 1.43
Free cash flow per shareRs 11.24
Efficiency
Asset turnover0.56x
Fixed asset turnover1.55x
Inventory turnover8.31x
Inventory days44 days
Debtor days123 days
Debtors turnover2.97x
Creditor days63 days
Cash conversion cycle116 days
Working capital days42 days
Leverage
Total debtRs 119 Cr
Cash and bankRs 143 Cr
Net debtRs -25 Cr
Debt to equity0.30x
Net debt / EBITDA-0.11x
Interest coverage2.36x
Current ratio (filing 2026-03-31)2.80x
Quick ratio (filing 2026-03-31)2.69x
Trade payables (filing 2026-03-31)Rs 143 Cr
Owners' fund to total sources68.80%
Debt to assets20.80%
Cash flow
Cash from Operating Activity (latest year)Rs 14 Cr
Cash from Investing Activity (latest year)Rs -130 Cr
Cash from Financing Activity (latest year)Rs 121 Cr
Net Cash Flow (latest year)Rs 6 Cr
Free cash flow (latest year)Rs 113 Cr
FCFE (approx.: FCF + change in debt)Rs 92 Cr
Cash from ops / profit, 5 years3.18x
Sales to cash flow22.14x
Statement figures
Net sales (TTM)Rs 890 Cr
Net sales (latest year)Rs 318 Cr
Sales (latest quarter)Rs 246 Cr
Operating profit excl. other income (latest year)Rs 16 Cr
Operating profit (latest quarter)Rs 64 Cr
Other income (TTM)Rs 20 Cr
EBITDA (TTM)Rs 227 Cr
PBDT (TTM)Rs 165 Cr
Profit before tax (TTM)Rs 84 Cr
Tax (latest year)Rs -6 Cr
Net profit (TTM)Rs 59 Cr
Net profit (latest year)Rs -21 Cr
Net profit (latest quarter)Rs -9 Cr
Depreciation (TTM)Rs 81 Cr
Depreciation (latest quarter)Rs 23 Cr
Interest (TTM)Rs 62 Cr
Cost of goods sold (latest year)Rs 121 Cr
Total expenditure (latest year)Rs 302 Cr
Total income (latest year)Rs 327 Cr
Share capitalRs 2 Cr
ReservesRs 391 Cr
Shareholders' fundsRs 393 Cr
Total assetsRs 571 Cr
Net blockRs 205 Cr
Capital work in progressRs 43 Cr
ReceivablesRs 107 Cr
InventoryRs 15 Cr
Other liabilitiesRs 59 Cr
Shares outstanding (crore)10.06
Ownership
Promoter holding63.85%
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | NEPHROPLUS | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -8.5% | -2.8% | -5.8 pts |
| 1 month | -5.9% | -6.8% | +0.9 pts |
| 3 months | -3.4% | -7.6% | +4.2 pts |
| 6 months | +28.0% | +0.4% | +27.6 pts |
14 mutual fund schemes hold about ₹206 Cr.
Over three months 3 bought more and 5 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| SBI Healthcare Opp Fund | 1.18% | 68 | +13% |
| DSP Healthcare Fund | 1.13% | 43 | -4% |
| SBI Children's Fund-Investment Plan | 0.34% | 27 | -7% |
| Baroda BNP Paribas Small Cap Fund | 1.17% | 15 | -25% |
| Helios Small Cap Fund | 1.02% | 15 | +2% |
| ICICI Pru Retirement Fund-Hybrid Aggressive Plan | 0.98% | 12 | -2% |
| Bandhan Innovation Fund | 0.29% | 8 | +100% |
| Baroda BNP Paribas Health and Wellness Fund | 1.35% | 7 | -24% |
| WOC Pharma and Healthcare Fund | 0.61% | 6 | +21% |
| Union Value Fund | 0.99% | 4 | +3% |
| Motilal Oswal Services Fund | 0.73% | 1 | -5% |
| Bandhan BSE Healthcare Index Fund | 0.09% | 0 | +0% |
| Motilal Oswal Active Momentum Fund | 0.00% | 0 | -100% |
| Motilal Oswal BSE 1000 Index Fund | 0.01% | 0 | +4% |
Red flags
F-score 3 of 8| look | Share dilution Share count up 11% in a year |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹282 Cr +23.7% vs Jun 2025.
Net profit ₹32 Cr +33.3%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Dr Lal Pathlabs Ltd | 32,737 | 58.2 | 28.0 % |
| Vijaya Diagnostic Centre Ltd | 15,192 | 81.0 | 20.5 % |
| Metropolis Healthcare Ltd | 11,665 | 56.0 | 17.8 % |
| Thyrocare Technologies Ltd | 8,708 | 48.2 | 35.4 % |
| Suraksha Diagnostic Ltd | 1,847 | 51.6 | 17.3 % |
| Krsnaa Diagnostics Ltd | 1,791 | 18.1 | 12.7 % |
| 3B Blackbio DX Ltd | 1,396 | 25.1 | 25.5 % |
| One Global Service Provider Ltd | 1,046 | 14.1 | 87.0 % |
| Health X Platform Ltd | 923 | 0.03 % | |
| Gaudium IVF and Women Health Ltd | 830 | 35.9 | 29.3 % |
| Chandan Healthcare Ltd | 581 | 22.1 | 23.3 % |
| Pramodini Medicare Ltd | 259 | 14.9 | 41.8 % |
| Aspira Pathlab & Diagnostics Ltd | 148 | 2.84 % | |
| Choksi Laboratories Ltd | 132 | 69.2 | 9.44 % |
| Star Imaging and Path Lab Ltd | 131 | 6.80 | 26.1 % |
No bulk or block deals on record.
No corporate actions on record.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Scrip PE is greater than 50 (4 trailing quarters)
Quick answers
What is the market cap of Nephrocare Health Services Ltd?
Nephrocare Health Services Ltd (NEPHROPLUS) has a market capitalisation of Rs 6,671 Cr. at the 2026-10-01 close.
What is the P/E ratio of Nephrocare Health Services Ltd?
Nephrocare Health Services Ltd trades at a P/E of 78.4 on trailing twelve-month profit, at the 2026-10-01 close.
What were Nephrocare Health Services Ltd's latest quarterly results?
In the Jun 2026 quarter, Nephrocare Health Services Ltd sales was Rs 282 Cr (+23.7% vs Jun 2025) and net profit was Rs 32 Cr.
What is the 52-week high and low of Nephrocare Health Services Ltd?
The 52-week high is Rs 781.50 and the 52-week low is Rs 446.00.